Victory Capital Management Inc. Trims Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Victory Capital Management Inc. reduced its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 2.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,199 shares of the biopharmaceutical company’s stock after selling 1,543 shares during the quarter. Victory Capital Management Inc. owned about 0.06% of Intra-Cellular Therapies worth $5,195,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Avior Wealth Management LLC increased its stake in Intra-Cellular Therapies by 3.0% during the third quarter. Avior Wealth Management LLC now owns 4,473 shares of the biopharmaceutical company’s stock worth $327,000 after acquiring an additional 131 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Intra-Cellular Therapies by 1.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company’s stock worth $748,000 after acquiring an additional 141 shares during the last quarter. CIBC Asset Management Inc increased its stake in Intra-Cellular Therapies by 5.3% during the fourth quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 150 shares during the last quarter. Pallas Capital Advisors LLC increased its stake in Intra-Cellular Therapies by 6.4% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 192 shares during the last quarter. Finally, Assetmark Inc. increased its stake in Intra-Cellular Therapies by 9.1% during the third quarter. Assetmark Inc. now owns 2,477 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 207 shares during the last quarter. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Trading Down 0.1 %

ITCI opened at $131.26 on Friday. The stock has a market cap of $13.96 billion, a price-to-earnings ratio of -150.87 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 1 year low of $63.87 and a 1 year high of $131.40. The stock has a fifty day moving average price of $123.95 and a 200 day moving average price of $95.54.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, sell-side analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ITCI shares. Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Mizuho downgraded Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Finally, StockNews.com assumed coverage on Intra-Cellular Therapies in a report on Wednesday. They issued a “hold” rating on the stock. Ten analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $106.08.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.